AMARIN CORP PLC\UK
Moat Score — Amarin Corporation plc
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Amarin's most durable asset is its landmark REDUCE-IT cardiovascular outcomes trial data and international regulatory approvals, though its core U.S. composition-of-matter patents on icosapent ethyl have already been lost to generic competition. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Amarin has no cost advantage in manufacturing icosapent ethyl versus generic competitors, who can produce the chemically equivalent compound at lower cost once patent protection lapses. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Branded Vascepa has largely lost U.S. pricing power due to generic icosapent ethyl competition, though the company retains somewhat better pricing in international markets where patent protection and branded positioning remain more intact. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in pharmaceutical sales; the value of Vascepa to one patient or physician does not increase because other patients or physicians also use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Patients and physicians face minimal switching costs to a bioequivalent generic icosapent ethyl product once available, which is precisely the dynamic that has eroded Amarin's U.S. branded revenue. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The cardiovascular risk-reduction drug market is large and supports many therapies and now multiple generic icosapent ethyl suppliers, so Amarin gains little protection from efficient-scale dynamics in its core U.S. market. |